Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Lu AF87908 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 03 Aug 2023 Status changed from active, no longer recruiting to completed.
- 16 Jun 2023 Planned End Date changed from 15 Aug 2023 to 19 Jul 2023.
- 16 Jun 2023 Planned primary completion date changed from 15 Aug 2023 to 19 Jul 2023.